International Assets Investment Management LLC Purchases New Position in Hologic, Inc. (NASDAQ:HOLX)

International Assets Investment Management LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 13,290 shares of the medical equipment provider’s stock, valued at approximately $950,000.

Several other institutional investors have also added to or reduced their stakes in the business. CWM LLC increased its holdings in Hologic by 5.8% in the 3rd quarter. CWM LLC now owns 6,972 shares of the medical equipment provider’s stock worth $484,000 after buying an additional 384 shares in the last quarter. AE Wealth Management LLC raised its holdings in shares of Hologic by 23.7% during the third quarter. AE Wealth Management LLC now owns 5,504 shares of the medical equipment provider’s stock valued at $382,000 after purchasing an additional 1,056 shares during the last quarter. HB Wealth Management LLC lifted its position in Hologic by 18.1% during the third quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 884 shares during the period. SG Americas Securities LLC boosted its holdings in Hologic by 49.5% in the third quarter. SG Americas Securities LLC now owns 47,420 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 15,706 shares during the last quarter. Finally, Argus Investors Counsel Inc. grew its position in Hologic by 4.8% in the 3rd quarter. Argus Investors Counsel Inc. now owns 11,875 shares of the medical equipment provider’s stock worth $824,000 after purchasing an additional 549 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders have sold a total of 32,846 shares of company stock worth $2,473,443 over the last quarter. Insiders own 1.75% of the company’s stock.

Hologic Stock Up 1.1 %

HOLX opened at $76.22 on Tuesday. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The stock has a market cap of $17.89 billion, a price-to-earnings ratio of 36.12, a price-to-earnings-growth ratio of 2.55 and a beta of 1.00. The firm’s fifty day moving average is $75.80 and its 200 day moving average is $72.64.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.07 earnings per share. On average, sell-side analysts forecast that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Wednesday, April 10th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. UBS Group raised their price objective on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and upped their target price for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Finally, Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Hologic currently has a consensus rating of “Hold” and an average target price of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.